- BeiGene's (NASDAQ:BGNE) XGEVA (denosumab) has been approved in China for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma (MM).
- XGEVA is developed by Amgen (NASDAQ:AMGN) and licensed to BeiGene in China under a collaboration inked in October 2019 to develop cancer therapies.
- In October 2019, BeiGene in-licensed XGEVA from Amgen (AMGN).
- XGEVA targets the RANKL pathway to prevent the formation, function and survival of osteoclasts, which break down bone.
- https://seekingalpha.com/news/3638223-beigenes-xgeva-okd-in-china-for-bone-metastases-due-to-cancer
Thursday, November 19, 2020
BeiGene's Xgeva OK'd in China for bone metastases due to cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.